The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).
David L. Porter
Research Funding - Novartis
Noelle V. Frey
No relevant relationships to disclose
Alison W. Loren
No relevant relationships to disclose
Bruce Levine
Employment or Leadership Position - University of Pennsylvania
Research Funding - Novartis
Michael Kalos
Employment or Leadership Position - University of Pennsylvania
Holly McConville
No relevant relationships to disclose
Joan Gilmore
No relevant relationships to disclose
Anne Chew
No relevant relationships to disclose
Angela Shen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Charlene So
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Michele Sharr
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Patricia Ann Wood
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Carl H. June
Honoraria - Novartis
Research Funding - Novartis